Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership PT Bio Farma (Persero) Oct 21, 2025 15:45 HKT/SGT Read More
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" Eisai Oct 14, 2025 16:54 HKT/SGT Read More
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease Eisai Oct 08, 2025 11:03 HKT/SGT Read More
Eisai Highlights Breadth of Oncology Research at ESMO 2025 Eisai Oct 03, 2025 17:01 HKT/SGT Read More
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China Eisai Sep 29, 2025 09:33 HKT/SGT Read More
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication China Medical System Holdings Limited Sep 28, 2025 16:00 JST Read More
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia Eisai Sep 24, 2025 18:04 HKT/SGT Read More
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies China Medical System Holdings Limited Sep 23, 2025 13:15 JST Read More
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation Eisai Sep 17, 2025 17:20 HKT/SGT Read More
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes HighTide Therapeutics Inc. Sep 17, 2025 08:00 HKT/SGT Read More
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 Eisai Sep 08, 2025 16:49 HKT/SGT Read More
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 Eisai Sep 04, 2025 09:56 HKT/SGT Read More
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Eisai Sep 03, 2025 10:32 HKT/SGT Read More
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D Everest Medicines Limited Sep 01, 2025 21:55 JST Read More
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Sep 01, 2025 12:44 HKT/SGT Read More
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma Eisai Aug 29, 2025 17:17 HKT/SGT Read More
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) Eisai Aug 25, 2025 18:30 HKT/SGT Read More
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Successfully Carries Out Space Protein Crystallization Experiments TANAKA MIRAI Lab. Aug 22, 2025 02:00 HKT/SGT Read More
